Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in moderately to severely active ulcerative colitis
NCT05767021Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Primary endpoint: Urgency Numeric Rating Scale at 12 weeks. Started May 2023; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05767021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767021.